Topics

"Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients" Drugs and Medication Database

19:30 EST 26th January 2020 | BioPortfolio

Here are the most relevant "Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients" Drugs and Medications that we have found in our database.

More Information about "Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients" on BioPortfolio

We have published hundreds of Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients news stories on BioPortfolio along with dozens of Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients Clinical Trials and PubMed Articles about Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients Companies in our database. You can also find out about relevant Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients Drugs and Medications on this site too.

Showing "Study Evaluate Route Administration Ofatumumab Patients" Drugs and Medications, all 3

Possibly Relevant

Arzerra [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab) injection, for intravenous useInitial U.S. Approval: 2009

Imbruvica [pharmacyclics llc]

These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA (ibrutinib) capsules, for oral useIMBRUVICA (ibrutinib) tablets, for oral useInitial U.S. Approva

Copiktra [verastem, inc.]

These highlights do not include all the information needed to use COPIKTRA safely and effectively. See full prescribing information for COPIKTRA. COPIKTRA (duvelisib), capsules for oral use Initial U.S. Approval: 2018



Quick Search